DSpace@İnönü

Yazar "Hacioglu, MB" için listeleme

Yazar "Hacioglu, MB" için listeleme

Sırala: Sıra: Sonuçlar:

  • Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas 
    Cicin, I; Ozatli, T; Turkmen, E; Ozturk, T; Ozcelik, M; Cabuk, D; Gokdurnali, A; Balvan, O; Yildiz, Y; Seker, M; Ozdemir, N; Yapar, B; Tanriverdi, O; Gunaydin, Y; Menekse, S; Oksuzoglu, B; Aksoy, A; Erdogan, B; Hacioglu, MB; Arpaci, E; Sevinc, A (2016)
    Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are ...
  • Effectiveness and safety of cabazitaxel chemotherapy for metastatic 
    Suner, A; Aydin, D; Hacioglu, MB; Dogu, GG; Imamoglu, GI; Menekse, S; Pilanci, KN; Yazici, OK; Koca, D; Karaagac, M; Akyol, M; Akman, T; Ergen, S; Avci, N; Kacan, T; Bozkurt, O; Kefeli, U; Urakci, Z; Araz, M; Arpaci, E; Harputlu, H; Sevinc, A (2016)
    OBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, ...
  • Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas 
    Cicin, I; Ozatli, T; Turkmen, E; Ozturk, T; Ozcelik, M; Cabuk, D; Gokdurnali, A; Balvan, O; Yildiz, Y; Seker, M; Ozdemir, N; Yapar, B; Tanriverdi, O; Gunaydin, Y; Menekse, S; Oksuzoglu, B; Aksoy, A; Erdogan, B; Hacioglu, MB; Arpaci, E; Sevinc, A (2016)
    Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are ...
  • Efficacy of regorafenib in the second-and third-line setting for 
    Hacioglu, MB; Kostek, O; Karabulut, S; Tastekin, D; Goksu, SS; Alandag, C; Akagunduz, B; Bilgetekin, I; Caner, B; Sahin, AB; Yildiz, B; Kose, F; Kaplan, MA; Gulmez, A; Dogan, E; Guven, DC; Gurbuz, M; Ergun, Y; Karaagac, M; Demiray, AG; Turker, S; Sakalar, T; Ozkul, O; Telli, TA; Sahin, S; Kilickap, S; Bilici, A; Erdogan, B; Cicin, I (2020)
    Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of ...